6LJ0 Stock Overview
A clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Matinas BioPharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.69 |
| 52 Week High | US$20.75 |
| 52 Week Low | US$1.45 |
| Beta | 1.64 |
| 11 Month Change | 0% |
| 3 Month Change | -60.06% |
| 1 Year Change | -76.40% |
| 33 Year Change | -94.57% |
| 5 Year Change | -91.32% |
| Change since IPO | -98.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6LJ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 1.1% |
| 1Y | -76.4% | -8.5% | 18.9% |
Return vs Industry: 6LJ0 underperformed the German Biotechs industry which returned -8.5% over the past year.
Return vs Market: 6LJ0 underperformed the German Market which returned 18.9% over the past year.
Price Volatility
| 6LJ0 volatility | |
|---|---|
| 6LJ0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 6LJ0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 32 | Jerry Jabbour | www.matinasbiopharma.com |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
Matinas BioPharma Holdings, Inc. Fundamentals Summary
| 6LJ0 fundamental statistics | |
|---|---|
| Market cap | €19.02m |
| Earnings (TTM) | -€21.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 6LJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6LJ0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$13.78m |
| Gross Profit | -US$13.78m |
| Other Expenses | US$9.14m |
| Earnings | -US$22.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6LJ0 perform over the long term?
See historical performance and comparison